Kato R, Kamatari T (eds).

[Drug Metabolism] (In Japanese)

Tokyo Kagaku Dojin (2000)

Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR.

Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.

Dig Liver Dis 37:282-97 (2005)
DOI:10.1016/j.dld.2004.09.029

Gearry RB, Barclay ML.

Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.

J Gastroenterol Hepatol 20:1149-57 (2005)
DOI:10.1111/j.1440-1746.2005.03832.x

Gilissen LP, Derijks LJ, Verhoeven HM, Bierau J, Hooymans PM, Hommes DW, Engels LG.

Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease.

Dig Liver Dis 39:182-6 (2007)
DOI:10.1016/j.dld.2006.05.026

Fischel JL, Formento P, Ciccolini J, Etienne-Grimaldi MC, Milano G.

Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.

Anticancer Drugs 15:969-74 (2004)
DOI:10.1097/00001813-200411000-00006

Shimma N, Umeda I, Arasaki M, Murasaki C, Masubuchi K, Kohchi Y, Miwa M, Ura M, Sawada N, Tahara H, Kuruma I, Horii I, Ishitsuka H.

The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine.

Bioorg Med Chem 8:1697-706 (2000)
DOI:10.1016/S0968-0896(00)00087-0

Chung YL, Troy H, Judson IR, Leek R, Leach MO, Stubbs M, Harris AL, Griffiths JR

Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.

Clin Cancer Res 10:3863-70 (2004)
DOI:10.1158/1078-0432.CCR-03-0237

Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Clin Cancer Res 7:2182-94 (2001)

Kita T, Tanigawara Y, Chikazawa S, Hatanaka H, Sakaeda T, Komada F, Iwakawa S, Okumura K.

N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients.

Biol Pharm Bull 24:544-9 (2001)
DOI:10.1248/bpb.24.544

Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, Shibata C, Sasaki I

5-fu metabolism in cancer and orally-administrable 5-fu drugs.

Cancers (Basel) 2:1717-30 (2010)
DOI:10.3390/cancers2031717

Wang P, Pradhan K, Zhong XB, Ma X

Isoniazid metabolism and hepatotoxicity.

Acta Pharm Sin B 6:384-392 (2016)
DOI:10.1016/j.apsb.2016.07.014

Klein DJ, Boukouvala S, McDonagh EM, Shuldiner SR, Laurieri N, Thorn CF, Altman RB, Klein TE

PharmGKB summary: isoniazid pathway, pharmacokinetics.

Pharmacogenet Genomics 26:436-44 (2016)
DOI:10.1097/FPC.0000000000000232

Yamada S, Richardson K, Tang M, Halaschek-Wiener J, Cook VJ, Fitzgerald JM, Elwood K, Marra F, Brooks-Wilson A

Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity.

Pharmacogenomics J 10:524-36 (2010)
DOI:10.1038/tpj.2010.5

Vlasits J, Jakopitsch C, Bernroitner M, Zamocky M, Furtmuller PG, Obinger C

Mechanisms of catalase activity of heme peroxidases.

Arch Biochem Biophys 500:74-81 (2010)
DOI:10.1016/j.abb.2010.04.018

Khan SR, Morgan AG, Michail K, Srivastava N, Whittal RM, Aljuhani N, Siraki AG

Metabolism of isoniazid by neutrophil myeloperoxidase leads to isoniazid-NAD(+) adduct formation: A comparison of the reactivity of isoniazid with its known human metabolites.

Biochem Pharmacol 106:46-55 (2016)
DOI:10.1016/j.bcp.2016.02.003

Forbes LV, Furtmuller PG, Khalilova I, Turner R, Obinger C, Kettle AJ

Isoniazid as a substrate and inhibitor of myeloperoxidase: identification of amine adducts and the influence of superoxide dismutase on their formation.

Biochem Pharmacol 84:949-60 (2012)
DOI:10.1016/j.bcp.2012.07.020

Nguyen M, Quemard A, Broussy S, Bernadou J, Meunier B

Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis.

Antimicrob Agents Chemother 46:2137-44 (2002)
DOI:10.1128/AAC.46.7.2137-2144.2002

Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr, Sacchettini JC

Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.

Science 279:98-102 (1998)
DOI:10.1126/science.279.5347.98

Argyrou A, Vetting MW, Blanchard JS

New insight into the mechanism of action of and resistance to isoniazid: interaction of Mycobacterium tuberculosis enoyl-ACP reductase with INH-NADP.

J Am Chem Soc 129:9582-3 (2007)
DOI:10.1021/ja073160k